Evaluating the Effect of Cerebrolysin as an Adjuvant to Standard Therapy in Patients with Acute Ischemic Stroke: A Prospective Observational Study.
Kandasamy G, Arumugam V, Orayj K, Alshahrani AM, Alanazi TS, Hmlan A, Venugopal JP · 2025 · Medicina (Kaunas, Lithuania). 2025.
Study findings
Day-14 NIHSS scores were 3.4 with adjunctive Cerebrolysin versus 4.8 with standard care, from baseline scores of 9.9 and 10.1. Functional measures also favored the adjunctive group.
- Population and setting
- 143 adults: 73 adjunctive treatment, 70 standard care; recruited in 2016–2018
- Evidence type
- Human comparative study
- Source language
- eng
- Title source
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
Study limitations
- Nonrandomized single-center comparison with only 14 days of follow-up.
- Published in 2025 but participants were recruited in 2016–2018; publication date is not the study date.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Abstract-level record
Source access and review scope
Indexed primary-publication abstract checked; full methods and tables not appraised.
Recorded source-check date: 2026-10-08. This date does not imply a completed systematic review.
Citation and original source
Original source: Kandasamy G, Arumugam V, Orayj K, Alshahrani AM, Alanazi TS, Hmlan A, Venugopal JP. Evaluating the Effect of Cerebrolysin as an Adjuvant to Standard Therapy in Patients with Acute Ischemic Stroke: A Prospective Observational Study. Medicina (Kaunas, Lithuania). 2025. 2025.
Molekul research summary: https://molekul.io/research/refresh-41010922. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry